Foundation Leadership
President
- Robert F. (Bobby) Anderson (contact)
Board of Trustees
Chairman
- Kim D. Wheless
Vice Chairman
- Michael A. Meagher
Members
- Victoria L. Brown, PhD
- George S. Conklin
- John A. Gillean, MD
- Beppino C. Giovanella, PhD
- John E. Hine
- Peter D. de Ipolyi, MD
- Raymond J. Khoury
- Donna S. Lewis
- Ethan A. Natelson, MD
- Sister Rosanne Popp, MD
- Michael W. Ross, PhD
- Thomas C. Royer, MD
- Lin Mills Smolensky
- John S. Stehlin, Jr., MD
- Nancy B. White
News
Two Houston CHRISTUS Hospitals and Stehlin Soon to Join Houston Methodist
CHRISTUS Stehlin Foundation for Cancer Research will join CHRISTUS St. Catherine and CHRISTUS St. John in a new partnership with Houston Methodist.
Nearly 14 Million Cancer Survivors in U.S.
There are currently 13.7 million cancer survivors in the United States and the number is expected to rise by 31 percent to 18 million by 2022, according to a new report. >> Click article title for more.
'Watchful Waiting' Often Best for Older Kidney Cancer Patients
A new study suggests that sometimes simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors. A surgical oncologist said that the findings, "should allow clinicians and patients to feel more comfortable about surveillance, particularly for the 'oldest old' and those patients with multiple [other health conditions] that would make surgery especially high risk." >> Click on article title for more.
Our Team
“Compared with other anticancer drugs at similar stages of development, camptothecins have demonstrated a much higher anticancer activity. Camptothecins can be envisioned as the ultimate anticancer drug when fully developed.”
National Academy of Science, 1995
Stay Connected
Affiliates and Resources
